(S)-2-ethoxy-3-(4-(2-(5-methyl-2-(5-methyl thiophen-2-yl)oxazol-4-yl)ethoxy)phenyl)propanoic acid | 696661-91-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (S)-2-ethoxy-3-(4-(2-(5-methyl-2-(5-methyl thiophen-2-yl)oxazol-4-yl)ethoxy)phenyl)propanoic acid
• 英文别名: (2S)-2-ethoxy-3-(4-{2-[5-methyl-2-(5-methylthiophen-2-yl)-1,3-oxazol-4-yl]ethoxy}phenyl)propanoic acid；(2S)-2-ethoxy-3-[4-[2-[5-methyl-2-(5-methylthiophen-2-yl)-1,3-oxazol-4-yl]ethoxy]phenyl]propanoic acid
• CAS: 696661-91-3
• 化学式: C₂₂H₂₅NO₅S
• 分子量: 415.51
• InChiKey: KACYCSASEXQENA-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  <5-methyl-2-(5-methyl-2-thienyl)oxazo-4-yl>acetic acid methyl ester 在 lithium aluminium tetrahydride 、 水 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 (S)-2-ethoxy-3-(4-(2-(5-methyl-2-(5-methyl thiophen-2-yl)oxazol-4-yl)ethoxy)phenyl)propanoic acid
  参考文献：
  名称：

  Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents

  摘要：

  In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, novel thiophene substituted oxazole containing alpha-alkoxy-phenylpropanoic acid derivatives are designed as highly potent PPAR alpha/gamma dual agonists. These compounds were found to be efficacious at picomolar concentrations. Lead compound 18d has emerged as very potent PPAR alpha/gamma dual agonist demonstrating potent antidiabetic and lipid lowering activity at a very low dose and did not exhibit any significant signs of toxicity in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.020

文献信息

• [EN] SUBSTITUTED ARALKYL DERIVATIVES<br/>[FR] DERIVES D'ARALKYLE SUBSTITUES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2004046119A1

  公开（公告）日：2004-06-03

  The present invention relates to novel substituted aralkyl derivatives of the general formula (I) & (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一般式(I)和(IIIa)的新型取代芳基衍生物，它们的衍生物、类似物、互变异构体、药学上可接受的盐、药学上可接受的溶剂化物、含有它们的药物组合物、这些化合物在医学上的用途以及其制备中涉及的中间体。
• Substituted aralkyl derivatives
  申请人：Lohray B. Braj

  公开号：US20060142277A1

  公开（公告）日：2006-06-29

  The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新的通式（I）和（IIIa）的取代芳基烷基衍生物，它们的衍生物，类似物，互变异构体，药学上可接受的盐，药学上可接受的溶剂化合物，包含它们的制药组合物，以及这些化合物在医学上的应用和其制备中所涉及的中间体。
• SUBSTITUTED ARALKYL DERIVATIVES
  申请人：CADILA HEALTHCARE LTD.

  公开号：EP1569916A1

  公开（公告）日：2005-09-07